Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)
Others
Ratios

BioNexus Gene Lab (BGLC) Cost of Revenue (2018 - 2025)

Historic Cost of Revenue for BioNexus Gene Lab (BGLC) over the last 8 years, with Q3 2025 value amounting to $2.2 million.

  • BioNexus Gene Lab's Cost of Revenue fell 597.71% to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.1 million, marking a year-over-year increase of 66.84%. This contributed to the annual value of $8.2 million for FY2024, which is 260.84% down from last year.
  • As of Q3 2025, BioNexus Gene Lab's Cost of Revenue stood at $2.2 million, which was down 597.71% from $1.9 million recorded in Q2 2025.
  • Over the past 5 years, BioNexus Gene Lab's Cost of Revenue peaked at $2.9 million during Q3 2021, and registered a low of $1.7 million during Q2 2024.
  • In the last 5 years, BioNexus Gene Lab's Cost of Revenue had a median value of $2.2 million in 2022 and averaged $2.3 million.
  • Examining YoY changes over the last 5 years, BioNexus Gene Lab's Cost of Revenue showed a top increase of 17795.93% in 2021 and a maximum decrease of 2604.35% in 2021.
  • BioNexus Gene Lab's Cost of Revenue (Quarter) stood at $2.8 million in 2021, then fell by 9.67% to $2.5 million in 2022, then dropped by 19.75% to $2.0 million in 2023, then grew by 10.37% to $2.2 million in 2024, then decreased by 2.19% to $2.2 million in 2025.
  • Its Cost of Revenue stands at $2.2 million for Q3 2025, versus $1.9 million for Q2 2025 and $1.8 million for Q1 2025.